Abbott agrees to settlement over closure of largest baby formula plant in the U.S.

Abbott Laboratories, one of the world’s leading medical device and health care companies, has agreed to a $385 million settlement to resolve a sprawling array of legal claims linked to the 2022 shutdown of its infant formula manufacturing facility in Sturgis, Michigan. The closure of the plant—the largest of its kind in the United States—precipitated a national supply chain catastrophe, forcing the Biden administration to intervene with emergency measures to prevent widespread shortages of essential infant nutrition. The settlement addresses lawsuits brought by the U.S. Department of Justice, various state Attorneys General, and several private relators, marking a significant step toward closing a chapter that severely tested the resilience of the American food supply chain.

Despite the substantial financial penalty, Abbott Laboratories maintains that the agreement does not constitute an admission of fault or liability. In a statement released on Monday, the company emphasized that government testing of unopened products collected from the homes of infants involved in the initial 2022 investigation yielded negative results for Cronobacter sakazakii, a bacterium capable of causing severe illness in neonates. Abbott further stated that there has never been a confirmed instance of an unopened, distributed Abbott infant formula testing positive for the pathogen.

A Chronology of the Crisis

The crisis originated in early 2022, following reports of infants falling ill after consuming formula produced at the Sturgis facility. The Food and Drug Administration (FDA) launched an intensive investigation into the site, uncovering various sanitary issues that prompted Abbott to issue a voluntary recall of several powdered infant formula brands, including the widely used Similac.

The timeline of the disruption was as follows:

• February 2022: Abbott Laboratories suspends production at the Sturgis facility and issues a massive product recall after the FDA identifies potential contamination risks and lapses in safety protocols.
• Spring 2022: The combination of the Sturgis shutdown, existing supply chain fragilities caused by the COVID-19 pandemic, and widespread consumer panic-buying creates a critical inventory void. Shelves across the U.S. sit empty, causing significant distress to parents and caregivers.
• May 2022: The Biden administration invokes the Defense Production Act to prioritize the delivery of raw materials to formula manufacturers and organizes "Operation Fly Formula," using Department of Defense aircraft to airlift millions of canisters of formula from Europe to alleviate the shortfall.
• June 2022: After extensive facility upgrades and regulatory oversight, the Sturgis plant resumes production.
• 2023-2024: Multiple legal actions proceed through federal and state courts, involving a complex network of whistleblowers, state regulators, and federal oversight bodies.
• Late 2024: The $385 million settlement is reached, bringing a formal resolution to the government-led litigation.

The Regulatory and Operational Landscape

The Sturgis incident highlighted a systemic vulnerability in the domestic infant formula market, which is characterized by extreme consolidation. In the United States, four companies—Abbott, Reckitt, Nestlé, and Perrigo—control roughly 90% of the market. This high level of concentration meant that the closure of a single facility created a "single point of failure," leaving the entire country exposed when that factory went offline.

The FDA’s role in the crisis also came under intense scrutiny. During subsequent congressional hearings, lawmakers questioned whether the agency acted with sufficient urgency when the initial whistleblower reports surfaced. The FDA’s internal review later acknowledged that communication lapses within the agency delayed the response, contributing to the severity of the shortage.

In response to the chaos, the Biden administration moved to permanently adjust import regulations to make it easier for foreign manufacturers to enter the U.S. market. By streamlining the approval process for international formula, the government aimed to foster a more competitive and less concentrated supply chain, theoretically insulating the market from future domestic plant failures.

Impact on Public Health and Consumer Trust

The 2022 shortage was not merely an economic issue; it became a public health emergency. For families reliant on specialized formula for infants with allergies or metabolic conditions, the scarcity was life-threatening. The stress on parents, who spent weeks scouring social media groups and driving hundreds of miles to find available stock, resulted in a significant erosion of trust in both corporate manufacturers and federal oversight agencies.

While Abbott’s legal defense has consistently pointed to the negative results for Cronobacter in its own products, the company faced criticism regarding its maintenance practices at the Sturgis site. Reports from the FDA inspection highlighted roof leaks, standing water, and failures in environmental monitoring, which the company subsequently invested millions of dollars to remediate. The company’s modernization efforts at the plant were part of a broader push to restore its reputation with both the government and the public.

Financial and Legal Implications

The $385 million settlement serves as a milestone in the litigation, but it does not represent the entirety of the financial impact on Abbott. The company incurred significant costs related to the recall, the temporary shutdown, and the logistical challenges of restarting the plant under stricter regulatory standards.

Interestingly, the legal landscape surrounding the event saw a shift in perspective as investigations deepened. While the initial regulatory response suggested a direct link between the Sturgis plant and the reported illnesses, the subsequent lack of definitive evidence in the product testing led to the closure of the criminal investigation previously initiated under the Trump administration. This nuance in the findings—where the facility was found to have sanitation issues, yet those specific issues could not be definitively linked to the pathogenic contamination of the infant formula—remains a point of contention among legal experts.

Broader Industry Implications

The resolution of this case leaves the infant formula industry with a new set of operating realities. First, the industry now operates under significantly heightened regulatory scrutiny from the FDA, with increased frequency of facility inspections and more rigorous reporting requirements for potential contamination.

Second, the supply chain model has undergone a forced evolution. Major manufacturers have invested in redundant capacity, and the government continues to incentivize a more diversified supply chain. The "just-in-time" delivery model, which proved so effective for efficiency but so fragile during a crisis, has been tempered by the necessity of higher buffer stocks.

Finally, the settlement underscores the power of the False Claims Act and the role of relators in corporate accountability. By providing a mechanism for whistleblowers to bring evidence of regulatory non-compliance to the federal government, the legal system has placed an additional layer of oversight on private industry, ensuring that internal lapses are more likely to reach the public eye.

As the industry moves forward, the $385 million settlement is viewed by many as a signal that the era of "self-policing" in food manufacturing has reached its limit. For Abbott Laboratories, the settlement offers a pathway to put the most disruptive legal challenges behind them. For the broader public, however, the 2022 crisis serves as a persistent reminder of the fragility of the nation’s food security and the necessity for robust, proactive regulation in the interest of public safety. The coming years will determine whether these structural and financial adjustments will be sufficient to prevent a recurrence of the supply shortages that left millions of American families in a state of crisis.